X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Jocelyn Ulrich

Jocelyn Ulrich Jocelyn Ulrich, MPH, is Deputy Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.

Recent Posts

Research and development continues long after a medicine is initially approved

By Jocelyn Ulrich  |    February 1, 2022
The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...   Read More

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

By Jocelyn Ulrich  |    January 24, 2022
New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The...   Read More

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

By Jocelyn Ulrich  |    November 18, 2021
COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and other...   Read More

ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response

By Jocelyn Ulrich  |    February 22, 2021
As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...   Read More

The next threat: Combatting antimicrobial resistance

By Jocelyn Ulrich  |    February 8, 2021
Since their discovery, antimicrobial medicines have revolutionized the fight against disease and today represent one of the greatest achievements in public health. But after decades of helping to...   Read More

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

By Jocelyn Ulrich  |    September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

R&D Focus: 5 things to know about the biopharmaceutical research ecosystem

By Jocelyn Ulrich  |    July 13, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

Clinical Trials Q&A: A patient’s perspective

By Jocelyn Ulrich  |    May 4, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Clinical Trials Q&A: Examining clinical trial design

By Jocelyn Ulrich  |    April 12, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Clinical Trials Q&A: Income disparities

By Jocelyn Ulrich  |    March 14, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."